A new scientific breakthrough may soon offer hope for people affected by Alzheimer’s disease. A group of researchers in Spain ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Lifeforce, the world's leading longevity medicine program, has introduced the Lifeforce Brain Protection Program, a first-of-its-kind solution for people wanting to proactively take control of their ...

Around 70% of college students report getting less than eight hours of sleep a night. With looming deadlines, buzzing social ...

Tim-3, a molecule involved in immune regulation, hinders plaque removal in Alzheimer’s disease. Blocking it in microglia improved brain health in mice, making it a potential treatment target. Tim-3 is ...

A research team at the Institute for Basic Science (IBS) has identified a previously unknown enzyme, SIRT2, that plays a key ...

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's disease (AD), but its role in the brain was unknown until now. Researchers used ...

Using advanced microscopes that capture brain cell anatomy and activity, a portion of a mouse's brain was mapped and rendered ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

GALES FERRY, Conn. (WTNH) — Within the past few years, the FDA approved two groundbreaking drugs that in trials were shown to reduce brain plaque by 27% in some Alzheimer’s patients.

The interaction between the brain and the vascular system could hold the key to lowering disease risk. According to the Alzheimer Society of Canada, one in four Canadians over the age of 85 is living ...